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The cyclotides are stable plant-derived mini-proteins with a
topologically circular peptide backbone and a knotted arrange-
ment of three disulfide bonds that form a cyclic cystine knot
structural framework. They display a wide range of pharmaceu-
tically important bioactivities, but their natural function is in
plant defense as insecticidal agents. To determine the influence
of individual residues on structure and activity in the prototypic
cyclotide kalata B1, all 23 non-cysteine residues were succes-
sively replaced with alanine. The structure was generally toler-
ant of modification, indicating that the framework is a viable
candidate for the stabilization of bioactive peptide epitopes.
Remarkably, insecticidal and hemolytic activities were both
dependent on a common, well defined cluster of hydrophilic
residues on one face of the cyclotide. Interestingly, this cluster is
separate from the membrane binding face of the cyclotides.
Overall, themutagenesis data provide an important insight into
cyclotide biological activity and suggest that specific self-asso-
ciation, in combination with membrane binding mediates
cyclotide bioactivities.
Cyclotides are a fascinating family of plant-derivedmini-pro-
teins of around 30 residues that are characterized by the topo-
logically unique combination of a head-to-tail cyclized back-
bone and a cystine knot. The original discovery of the
prototypic member kalata B1 (1) was guided by the indigenous
medicinal use in Africa of a tea made from the plant Olden-
landia affinis (Rubiaceae) to accelerate childbirth. Kalata B1
was identified as a uterotonic component of the plant, but its
unusual macrocyclic nature (2) and the fact that it was just one
member of a large family of related macrocyclic peptides were
elucidated only recently (3). Cyclotides have nowbeen reported
in several other species of the Rubiaceae (coffee) family (4, 5)
and in all tested members of the Violaceae (violet) plant family
(3, 6, 7) bringing the number of known cyclotides to over 100.
Individual plants contain a suite of dozens of cyclotides, and
analyses of crude plant extracts have suggested that thousands
more cyclotide sequences await discovery (8, 9), potentially
making them one of the largest known families of plant pro-
teins. Other examples of head-to-tail cyclized proteins have
recently also been reported in bacteria, plants, and animals
(10, 11).
Cyclotides display a wide range of biological activities. In
addition to their uterotonic activity (12), hemolytic (6), anti-
HIV4 (13), anti-bacterial (14), anti-tumor (15), anti-fouling
(16), and insecticidal (17) activities have been reported. The
mechanism(s) of action of these activities are unknown butmay
involve interactions with membranes (18, 19), possibly via self-
association of cyclotides to form multimeric species (20).
Reported structures of cyclotides show the presence of a sur-
face-exposed hydrophobic patch (2, 21) thatmay be involved in
such interactions. Their natural function in plants appears to be
as host defense agents against insect pests based on their potent
inhibition of growth and development of caterpillar larvae of
the cotton budworm and cotton bollworm (17, 22).
Fig. 1 shows the three-dimensional structure and amino acid
sequence of kalata B1 and highlights the knotted arrangement
of the three conserved disulfide bonds that are characteristic of
all cyclotides. The cystine knot and cyclic backbone account for
the exceptional resistance of the cyclotides to thermal, chemi-
cal, and enzymatic degradation compared with other peptides
of similar size (23). This chemical and biological resilience has
led to suggestions of the use of cyclotides as protein-engineer-
ing scaffolds for stabilizing bioactive peptide epitopes in the
optimization of peptide drugs (24–27).
The sequences of currently known cyclotides reveal subsets
of conserved and variable residues. In describing cyclotides it is
convenient to discuss their structures in terms of the six back-
bone loops between successive cysteine residues. The cycloti-
des may be regarded as a natural combinatorial template in
which substitutions occur in these loops, which protrude from
the cystine knot core (Fig. 1). Loop 1 is the most highly con-
served and contains a structurally important glutamate residue
that forms a network of hydrogen bonds to the backbone of the
first two residues of loop 3 (28). Cyclotide sequences have been
divided into the Mo¨bius and bracelet subclasses (3), which dif-
fer from one another mostly in loops 2, 3, and 5, but the char-
acteristic discriminating feature is a cis-Pro peptide bond in
loop 5 of the Mo¨bius subfamily, so named for its conceptual
180° twist of the circular backbone.
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Investigation of the contribution of individual residues to the
structural integrity and biological activities of the cyclotides is
crucial to facilitate their use in protein engineering or pharma-
ceutical applications. A clearer understanding of the structural
limitations of the cyclotide framework will greatly assist in
developing grafted analogues for use as peptide drugs so that
sequence modifications in structurally important regions can
be avoided. Understanding the basis for bioactivity will also
allow undesirable properties such as hemolytic activity to be
minimized in pharmaceutical applications.
A better appreciation of the structure-activity relationships
of the cyclotides also has the potential to help uncover the
mechanism(s) mediating their various bioactivities. Hence, in
the current studywe chemically synthesized a complete suite of
kalata B1 mutants, in which all residues, except for the six con-
served cysteines, were individually replaced with an alanine.
We analyzed these alanine mutants for structural and func-
tional perturbations relative to native kalata B1 and determined
their activities against insects and human cells. This approach
has provided significant insights into the structural constraints
of the cyclotide framework and the functional elements for bio-
activity and has provided a more detailed understanding of the
possible self-association process of these remarkable peptides.
EXPERIMENTAL PROCEDURES
Peptide Synthesis—t-Butoxycarbonyl-based solid phase pep-
tide synthesis was carried out using standard protocols (29).
Peptides were assembled using a thioester linker assembled on
resin, allowing subsequent cyclization by a modified form of
native chemical ligation (30). Synthesis was structured into
batches starting at V4, T8, T13, G18, and V25 that allowed bulk
assembly of the native peptide sequence then the resin was split
for assembly of individual alanine mutants in the terminal
loops.Hydrogen fluoride cleavagewas conducted on the depro-
tected resins following standard protocols (0 °C, 90 min, 90%
hydrogen fluoride/8% p-cresol/2% p-thiocresol). Crude cleav-
age products were purified by reversed phase C18 HPLC (1%/
min gradient of 90% acetonitrile/10%water/0.05% trifluoroace-
tic acid against 100% water/0.05% trifluoroacetic acid) to give
linear, reduced, C-terminally thioester-capped peptides. Pep-
tides were cyclized and oxidized in 0.1 M ammonium bicarbon-
ate at pH 8 containing 50% 2-propanol overnight and purified
as above. Purity of fractions was assessed using electrospray
ionization-mass spectrometry and analytical HPLC using a
2%/min gradient of the same solvents used for previous steps.
NMR Spectroscopy—NMR solutions for assignment and
structure determination were prepared in H2O:D2O (95:5) and
adjusted to pH 5.0–5.5 (or 3.0–3.5 for mutant E7A) with 0.1 M
NaOH and 0.1 M HCl. Samples for amide temperature coeffi-
cients were prepared in 100 mM sodium phosphate buffered at
pH 5.5 with 5% D2O adjusted to pH 5.0–5.5 (or 3.0–3.5 for
mutant E7A). Chemical shifts and amide temperature coef-
ficients for mutant E7A were compared with the wild-type
peptide under similar conditions. One- and two-dimen-
sional spectra were acquired on ARX 500-MHz or 600-MHz
spectrometers at 25 °C.
Structure Calculations—Preliminary structures were calcu-
lated using a torsion angle-simulated annealing protocol within
the program DYANA (31). Final structures were calculated
using simulated annealing and energy minimization protocols
within CNS version 1.1 (32). The starting structures were gen-
erated using random (, ) dihedral angles and energy-mini-
mized to produce structures with the correct local geometry. A
set of 50 structures was generated by a torsion angle-simulated
annealing protocol (33, 34). Structures consistent with
restraints were subjected to further molecular dynamics and
energy minimization in a water shell, as described by Linge and
Nilges (35). Structures were analyzed using PROMOTIF (36)
and PROCHECK-NMR (37). The Ramachandran statistics for
E7A are 75.8% of residues in the most favored and 24.2% in the
additionally allowed. ForT27A theRamachandran statistics are
87.4% in themost favored and 12.6% in the additionally allowed.
Hemolytic Assays—Stock solutions of each peptide were pre-
pared and standardized using UV spectroscopy (  6410
cm11 at 215 nm) at 350 M  3% then serially diluted in
triplicate. Human erythrocyteswerewashedwith repeated cen-
trifugation in phosphate-buffered saline (pH 7.4) to remove
serum contaminants. A 0.25% v/v stock solution was prepared
from the cell pellet, and 100 l of this stock was added to each
diluted peptide solution aliquot and then incubated at 37 °C for
1 h. After centrifugation of intact cells the percentage of hemol-
ysis of the supernatant wasmeasured by visual absorption spec-
troscopy ( 405 nm).
Insecticidal Assays—Adult Drosophila melanogaster were
allowed to oviposit overnight on plates (7 g of agar/7 g of
sucrose/260ml of water/70 ml of apple juice), and the resulting
eggs were collected and washed with repeated centrifugation.
The volume of eggs for each trial could only be approximated to
within  50 l, so the wild-type peptide was included in each
batch of assays on alanine mutants as a reference positive con-
trol. The egg pellet was diluted with 50% glycerol and aliquoted
into vials containing 3 ml of basic larval media (10 g of agar/80
g of cornmeal/200 g of yeast/850 ml of water/100 ml of trea-
cle/11 ml of 10% w/v nipogen/5 ml of propionic acid). Glycerol
was added to increase the viscosity to assist in homogeneous
dispersion of eggs throughout the suspension. After 24-h incu-
bation test compounds were added as UV absorption standard-
ized solutions to give final peptide concentrations of 230, 100,
FIGURE 1. The structure of the prototypic cyclotide kalata B1.A, the three-
dimensional structure of kalata B1 is shown in ribbon format, with the arrows
representing the -strands and the disulfide bonds shown in ball-and-stick
format. The cysteine residues are labeled with Roman numerals. B, the
sequence of kalata B1 with the disulfide bonds is shown as lines connecting
the cysteine residues. The number of different sequences for known cycloti-
des for each loop is shown outside the sequence.
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or 0 ppm (or 80, 35, and 0 M, respectively). Larvae were then
allowed tomature and pupate, and themass of total flies emerg-
ing was measured over 2–3 days.
Stability Assays—Enzymatic digests and acid hydrolysis con-
ditions were identical to those described previously (23).
Briefly, 1 mg/ml solutions of WT-kB1, G6A, or E7A were pre-
pared in 100 mM ammonium bicarbonate buffer (pH 8.1). The
enzymes used in these studies were trypsin, chymotrypsin, and
proteinase K. Enzymatic digestions (50:1 substrate-to-enzyme
ratio) were carried out at 37 °C with aliquots taken at set times
up to 24 h.DnaK fragment 2was used as a control to ensure that
the enzymes were active. With this control, and because we
were primarily interested in quantifying short term degrada-
tion, if present, no corrections for autodigestion of the enzymes
were required.Acid hydrolysis reactions (1mg/ml peptide solu-
tion in 1MHCl)were performed at two temperatures, 37 °C and
80 °C. Samples were analyzed by liquid chromatography/mass
spectrometry on an Agilent Series 1100 HPLC coupled to a
QSTAR mass spectrometer (Applied Biosystems, Foster City,
CA) equipped with an electrospray ionization source. Data
were collected, processed, and analyzed using the Analyst
QS1.1 software package. Thermal stability was assessed by
monitoring the quality of one-dimensional NMR spectra of
compounds in water at pH 5.0–5.5 for G6A and 3.0–3.5 for
E7A on cycling from 25 °C to 80 °C and back to 25 °C.
Metal Binding—Titration of 0.4 mM kalata B1, T27A, T16A,
and E7A with MnCl2 was performed at 40 °C, pH 5.0. One-
dimensional and total correlation spectroscopy spectra (80-ms
mixing time) were acquired at concentrations of 0 and 2.0 mM
MnCl2 on an ARX 500-MHz spectrometer. The paramagnetic
relaxation enhancement induced by Mn2 was qualitatively
characterized by relative cross-peak intensity in the total corre-
lation spectroscopy spectra,
RCIi 100%Ii
Mn2/Ii
0 (Eq. 1)
where IiMn2 and Ii0 are theHN-H cross-peak intensities in the
spectra of the sample with and without Mn2.
RESULTS
Synthesis—Kalata B1, the prototypic cyclotide, comprises 29
amino acids, including 6 cysteine residues. This alanine
mutagenesis study therefore required the synthesis of 23 indi-
vidual peptides, whichwas achieved by t-butoxycarbonyl-based
solid phase peptide synthesis. The cyclization was achieved
using a modified form (14, 38) of native chemical ligation (39)
and required that the linear precursor protein had a Cys at the
N terminus. For rapid and economical generation of mutants,
several large batches of the initial unmodified sequence were
synthesized, each from a different starting position.When only
a single loop (or two small loops) remained to be synthesized in
each batch, the resin was split into aliquots for selective alanine
mutagenesis of each residue in the loop(s). After cleavage from
the resin and purification, the peptides were cyclized and oxi-
dized at pH 8 in a 1:1 ammonium bicarbonate:2-propanol
buffer. Yields of the alaninemutants were inmany cases similar
to the native peptide and are summarized in Table 1. Notably,
variants of loops 2 and 5 gave significantly reduced yields of
correctly folded products, and the P24A andW23Amutants of
loop 5 did not form the native fold using folding conditions
applied for all other analogues. Mutant W23A was subse-
quently found to form a native fold upon addition of 1 mM
glutathione to the folding buffer. However, it was not assayed
with the other analogues. The decision to omit glutathione
from the original folding buffer was made to simplify the con-
ditions, rather than to optimize yield, and it is likely that
increased yields of individual mutants can be achieved after
optimization of the conditions.
Global Fold of Mutants as Assessed by NMR—The alanine
mutants of kalata B1 were dissolved in water and two-dimen-
sional NMR spectra were recorded at pH 5.0–5.5. The -pro-
ton chemical shifts of peptides are sensitive indicators of local
structure (40) and were used to highlight regions of perturbed
structure. The majority of alanine mutants had no significant
-H chemical shift perturbations compared with the wild-type
peptide, as shown in Fig. 2A. A small subset of mutants showed
some minor localized shift perturbations as shown in Fig. 2B.
The alanine mutants in loop 2 account for the majority of these
slightly perturbed structures. For mutant E7A several expected
peaksweremissing from the spectra at pH5.0–5.5 (presumably
due to broadening) but were present at pH 3.0–3.5, indicating
that this mutant is less able to form a rigid secondary structure
at the higher pH. Overall though, the chemical shift analysis
showed that generally no major structural changes are induced
by Ala substitution at any of the individual non-Cys residues
and that the overall cyclotide fold is maintained in all mutants.
Two alanine mutants were selected for full structure deter-
mination. Mutant E7A was selected to investigate the effect of
removal of the internal hydrogen-bonding network from the
glutamate side chain to the backbone amides of loop 3. Mutant
TABLE 1
Yields of folded Ala-mutant cyclotides and hemolytic and
insecticidal activity
Mutant Yielda Hemolytic activityb Insecticidal activityc
%
WT 100 69 100
G1A 50 68 102
L2A 71 12 100
P3A 7 37 31
V4A 82 34 115
G6A 54 1 2
E7A 46 1 0
T8A 64 8 15
V10A 21 49 108
G11A 25 61 91
G12A 11 11 31
T13A 25 46 118
N15A 68 4 68
T16A 100 5 55
P17A 50 49 83
G18A 79 62 119
T20A 64 62 131
S22A 36 59 118
W23A 0
P24A 0
V25A 21 9 133
T27A 68 69 119
R28A 68 15 100
N29A 39 54 102
a Relative to wild type (WT) at 100%. A typical wild-type kalata B1 oxidative folding
yield is 28% under comparable conditions.
b Relative to 100% lysis control standard of 10 l of 1% w/v Triton X-100.
c Relative to 100% control of wild-type peptide at 230 ppm (80 M) peptide (LD50
150 ppm (52 M)).
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T27A was selected as a relatively unperturbed example based
on the chemical shift data. The three-dimensional structures of
E7A and T27A were solved by simulated annealing using dis-
tance and angle restraints derived from two-dimensional NMR
spectra. Simulated annealing calculations gave ensembles of 20
low energy structures with backbone root mean square devia-
tions of 0.5 Å for E7A and 0.5 Å for T27A as summarized in
Table 2. The structures of E7A and T27A are shown in Fig. 3,
and they confirm that the overall fold of the mutants does not
substantially differ from the wild-type peptide.
Bioassays—The biological activities of the mutant peptides
were assessed in insecticidal and hemolytic assays. The former
activity is of interest because of the suggestion that the native
activity of cyclotides in plants is for
host defense against insects (17, 22),
and the latter activity is of interest
because it is a potentially deleteri-
ous effect should cyclotides be
applied in pharmaceutical applica-
tions. Insecticidal activity of the
alanine mutants was assessed by
measuring their impact on the
development of first and second
instars of Drosophila melanogaster
to adulthood. This assay consumed
3 mg per test compound by using
triplicates at twopeptide concentra-
tions. Triplicates were found to vary
by 10%. Wild-type kalata B1 and
alanine mutants gave reproducible
dose response curves with an
approximate LD50 of 150 ppm (52
M) for the wild-type peptide. The
mass of emerging adult flies varied
inversely with the mass of eggs ali-
quoted. The activity of the alanine
mutants relative to the wild-type
peptide is reported in Table 1,
where it is clear that substitution of
a specific set of individual residues
leads to a loss of activity. Thus,
despite the fact that noAla substitu-
tion causes a major structural
change, there are functional effects
of individual residues.
The relative hemolysis of human
erythrocytes caused by each mutant
is also shown in Table 1, which indi-
cates that residues in loops 1 and 3
along with a few other isolated resi-
dues strongly affect activity. Inter-
estingly, a comparison of the results
from both bioassays indicates that
hemolytic activity and insecticidal
activity depend on a similar subset
of residues.
Stability Analysis—The stability
of the G6A and E7A mutants was
assessed bymeasuring their resistance to proteolysis and to acid
hydrolysis. Mass spectra were examined for the presence of
intact peptides and/or degradation products, and the percent-
age of intact peptide remaining was plotted against time. The
two alanine mutants studied were completely impervious to
enzymatic digestion by the three endoproteinases trypsin, chy-
motrypsin, and proteinase K, as was the prototypic cyclotide
kalata B1. A linear control peptide degraded rapidly, with5%
remaining after 5 min under the same conditions. Acid hydrol-
ysis experiments were conducted at 37 °C and 80 °C. The for-
mer represents likely conditions in the human stomach (pH
1, 37 °C), whereas the higher temperature was used to force the
hydrolysis to occur and allow comparison of the stability of
FIGURE 2. Chemical shift differences of H signals for kalata B1 alanine mutants compared with the
wild-type peptide. A, mutants with minimal chemical shift changes from the wild-type peptide. B, mutants
with small local chemical shift changes from the wild-type peptide, particularly in loops 2 and 3. C, a structure
of kalata B1 showing the location of the residues that are most susceptible to chemical shift change on
substitution.
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the mutants to the wild-type cyclotide. At 37 °C, kalata B1, and
the two mutants were extremely stable, with no degradation
products observed for up to 24 h. At 80 °C, the peptides
degradedwithin 90min and showed similar degradation curves
from 0–90 min (data not shown).
Thermal stability was assessed by monitoring the one-dimen-
sionalNMRspectra of peptides on cycling from25 °C to 80 °C and
back to 25 °C. The spectra of both mutants were unchanged on
return to the original temperature, but E7A lostmore amidepeaks
at higher temperature than the wild-type peptide and G6A (data
not shown). Overall, the data suggest that the structures of the
mutants are highly resistant to extremes of temperature, pH, and
enzyme conditions, but the E7Amutant is slightly more suscepti-
ble to thermal unfolding and is more flexible.
Metal Binding—A representative group of mutants was
selected and compared with kalata B1 to examine the signifi-
cance of a putative metal binding site reported previously for
kalata B1 (41, 42). The mutants selected were E7A (an inactive
mutant without the carboxyl from E7), T16A (an inactive
mutant with the carboxyl), and T27A (an active mutant with
the carboxyl). A series of total correlation spectroscopy spectra
was measured for each peptide in solution with and without
Mn2. In the presence of Mn2 kalata B1, T16A and T27A
showed specific broadening of a defined set of amide signals,
consistent with previous reports for kalata B1 (41). There was
almost complete broadening of the amide signals from C14,
N15, and T16/A16, and significant broadening (i.e. 70%
attenuation) of loop 1 residues. By contrast, E7A showed signif-
icantly less broadening (supplemental Fig. S1). It is clear that
removal of the E7 carboxyl group reduces the effects of Mn2,
implicating it as the primary binding site.
DISCUSSION
In this study a complete suite of non-cysteine alanine
mutants was chemically synthesized and evaluated for struc-
tural and functional perturbations relative to the prototypic
cyclotide kalata B1. From this we have gained valuable insights
into the structural and functional contributions of specific res-
idues in the cyclotide kalata B1, and the data provide a basis for
understanding the mechanism of bioactivity of cyclotides.
Chemical solid phase peptide synthesis was used to generate
the 23 non-cysteine alaninemutants. Backbone cyclization was
achieved using a modified form of native chemical ligation in
which the linear peptide is synthesized with a C-terminal thio-
ester that is repeatedly exchanged
with cysteine thiol side chains, cul-
minating in the N-terminal cysteine
thiol that undergoes an irreversible
exchange with the N-terminal
amine to form the linking backbone
amide (43). Exploitation of this
mechanismpermitted designing the
synthesis with any linear precursor
that terminated in an N-terminal
cysteine. This allowed the synthesis
of the alanine mutants to start at
multiple different positions in the
sequence, allowing the resin from
a bulk synthesis of unmodified
cyclotide sequence to be split at the
appropriate point in the chain
assembly process to produce a set of
alanine mutants from the final
loop(s).
The mutants were cyclized and
subjected to oxidative folding in
ammonium bicarbonate/2-propa-
nol buffer, with the yields summa-
FIGURE3.Structureof alaninemutants andwild-typekalataB1. Left: three-dimensional structures of [E7A]-
kB1 determined using NMR spectroscopy. The 20 lowest energy structures are presented. Center: wild-type
kalata B1 (PDB code 1NB1). Right: mutant [T27A]-kB1. The disulfide bonds are shown in stick format and the
-strands as arrows.
TABLE 2
Structural statistics for the alaninemutants E7A and T27Aof kalata B1
E7A T27A
NMR distance and dihedral constraints
Distance constraints
Total NOE 261 184
Intra-residue
Inter-residue 261 184
Sequential (i j 1) 143 89
Medium range (i j 4) 49 36
Long-range (i j	 5) 69 59
Intermolecular
Hydrogen bonds 0 16
Total dihedral angle restraints 13 24
 9 12
 0 0
Structure statistics
Violations (mean S.D.)
Distance constraints (Å) 0.023 0.002 0.029 0.002
Dihedral angle constraints (°) 0.155 0.08 0.67 0.1
Max. dihedral angle violation (°) 2.8 2.6
Max. distance constraint violation (Å) 2 2
Deviations from idealized geometry
Bond lengths (Å) 0.003 0.0001 0.004 0.0002
Bond angles (°) 0.49 0.02 0.55 0.02
Impropers (°) 0.40 0.023 0.42 0.04
Average pairwise root mean square
deviationa (Å)
Heavy 0.90 0.2 1.09 0.2
Backbone 0.5 0.2 0.5 0.2
a Pairwise root mean square deviation was calculated among 20 refined structures.
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rized in Table 1. All of the mutants
formed a native fold in this buffer,
with the exception of W23A and
P24A, which involve substitutions
in loop 5. There was a variation in
yield of the correctly folded product
relative to the wild-type peptide;
peptides with lower yields had
mutations primarily concentrated
in loops 2 and 5, along with an iso-
lated example of P3A in loop 6 hav-
ing a low yield. The tight turns of
loops 2 and 5 and their close packing
in the structure of the native peptide
explain the sensitivity of these
regions to modification. Mutant
G12A had a particularly low yield
that is likely associated with its
broadened chromatographic peaks
during purification, suggesting that
this mutant may be conformation-
ally flexible. Introduction of a side
chain at this position appears to dis-
favor the positive -angle present
for this highly conserved glycine
that is present in almost half of
known cyclotide sequences (44).
The chemical shifts of the -pro-
tons of the alanine mutants relative
to the wild-type peptide gave useful
insights into the structural resil-
ience of the cyclotide framework.
Themajority of mutants had no sig-
nificant perturbations in shift,
showing that the framework is
highly tolerant to point substitu-
tions. A small subset of mutants
experienced minor local shift per-
turbations in the modified region
(Fig. 2B) generally in mutants that
also displayed lowered oxidative
folding yields. The most significant
changes in chemical shifts occurred
in loop 2, with loops 5 and 6 display-
ing the lowest variation in shifts.
Combined with the folding yield
observations this finding indicates
that future sequence modification
attempts may be more successful if
they concentrate on loops 3 or 6.
Loop 3 represents the most diverse
loop in terms of length in native
cyclotide sequences and is extended
into a short 310 helix in the bracelet
cyclotides (28).
The glutamic acid in loop 1 is
almost completely conserved in the
cyclotides, only conservatively sub-
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stituted with aspartic acid in one known sequence (45), and is
involved in a network of hydrogen bonds that stabilize the
structure (28). Analysis of the NMR structure of mutant E7A
was initially hindered by the poor spectra and an atypical pH
sensitivity of this compound. Numerous amide resonances
were not detected at pH 5.5, indicating that this mutant
undergoes a conformational exchange process not seen in the
wild-type peptide. These resonances were more readily
detected at lower pH, and the structure determined at pH 3.5 is
shown in Fig. 3 (left structures). Despite the loss of the network
of hydrogen bonds involving E7 the overall fold of E7A is main-
tained. Thus, themost significant structural effects ofmutation
of this conserved Glu are related to an increased flexibility of
the structure at higher pH. This effect is similar to the loss of
stability previously seen in acyclic permutants of kalata B1 (46,
47). The importance of the glutamic acid residue has also been
recently highlighted by the observation that methylation of this
side chain resulted in a 48-fold decrease in cytotoxicity activity
for the bracelet cyclotide cycloviolacin O2 (48). This finding
confirms the critical importance of this residue in both sub-
families of cyclotides. The structure of mutant T27A, deter-
mined as an example of a mutant that retained its bioactivity,
showed no significant difference to the wild-type peptide struc-
ture, as shown in Fig. 3 (right structures). This finding supports
the use of chemical shifts as a marker for a lack of structural
change for the other mutants also.
Superimposition of the bioassay results onto the structure of
the prototypic cyclotide highlights the stunning result that all of
the residues responsible for either insecticidal or hemolytic
activity are tightly clustered on a patch on one face of the mol-
ecule. As indicated in Fig. 4, most of the critical residues are
located in loop 1, and to a lesser degree at the beginning of loop
3, and the cationic Arg-28. The single exception is G12A, and,
as noted earlier, this is associated with a degree of conforma-
tional flexibility of this mutant, as judged by substantially
broadened HPLC peaks. The localization of residues responsi-
ble for activity in such a defined patch suggests that this patch is
associatedwith a crucial binding interaction. In general such an
interaction could be with a receptor, a membrane, or a cognate
binding protein. Because cyclotides have been demonstrated to
bind to membranes we first explored the possibility that the
bioactive patch is implicated in membrane binding.
We were at first very surprised to see that the surface-ex-
posed hydrophobic patch of kalata B1 shown in Fig. 4c is clearly
distinct from the residues that are crucial for bioactivity. Spin
label studies recently demonstrated that this surface-exposed
hydrophobic patch essentially forms the membrane binding
face of the cyclotide kalata B1, as shown in Fig. 4d (42). This
finding, together with the mutagenesis results from this work
clearly suggests that more than simple membrane interactions
must mediate bioactivity. The high level of sensitivity of bioac-
tivity to changes in hydrophilic rather than hydrophobic resi-
dues indicates that the activity of kalata B1 is not dependent on
gross physical characteristics and that the peptide does not act
as a simple detergent. This extreme sensitivity of activity to loss
of hydrophilic residues (e.g.T8A) or to small steric changes (e.g.
G6A) and the clustering of critical residues instead indicate that
a specific recognition process takes place that does not directly
involve the membrane binding face.
This recognition process could in principle bemediated via a
cellular receptor that is common to the many biological pro-
cesses (including hemolysis, insecticide activity, and anti-HIV
activity) that are sensitive to cyclotides, by self-recognition, or
by a combination of both. The very wide range of biological
activities of the cyclotides and consistent bioactivity across sub-
stantial cyclotide sequence variations are more consistent with a
non-receptor-basedmechanismand suggests that self-association
is an integral part of their biological activity. Self-association iswell
established in othermembrane-disrupting peptides (49, 50). Stud-
ies using analytical ultracentrifugation (20) indicate that kalata B2
(and to a lesser degree kalata B1) self-associate in sodium phos-
phate buffer to form tetramers and octamers. The lack of any
observable dimers or trimers indicates that cyclotides are capable
of a specific oligomerization process. We suggest here that this
specific oligomerization, along with subsequent membrane bind-
ing, is vital for cyclotide bioactivity.
The hydrophobic and putative self-recognition faces are
approximately orthogonal to each other in Fig. 4. This is con-
sistent with a self-association model in which four cyclotide
molecules come together, with the activity-influencing hydro-
philic surfaces facing inward and the hydrophobic surfaces ori-
ented together on one face of the tetramer (Fig. 5). Such a
reversible oligomerization could improve the absorption and
dispersion of cyclotides in biological systems by allowing both
the solubility of monomers in aqueous environments and of
oligomers in the membrane, switching the effective hydropho-
bicity of the peptides.
The dramatic effect of the loss of structural rigidity on bio-
activity seen inmutants E7A andG12A is also consistent with a
FIGURE4.Localizationof residues critical forhemolytic and insecticidal activityof kalataB1and thehydrophobicpatchof kalataB1. The figures on the
right are rotated 180° relative to those on the left. a, mutated residues giving20% hemolysis at 60M peptide concentration are shown in red. The wild-type
peptide displays 69% hemolysis at this concentration. Functionally essential residues without concomitant structural perturbation are seen to cluster on one
faceof themolecule aroundE7.b, the surfacepositionof residues critical for insecticidal activity.Mutated residuesgiving70% insecticidal activity at 230ppm
are shown in orange, relative to the wild-type peptide normalized to 100% activity. c, the hydrophobic residues of kalata B1 are highlighted in green, showing
a dominant hydrophobic patch on the lower section of the framework. d, membrane penetrating residues as measured by NMR shown in dark blue (42),
showing a correspondence with the dominant hydrophobic surface patch.
FIGURE 5. Schematic representation of proposed tetramer model of
kalata B1. The shaded regions represent the hydrophobic surface patch
known to be associated with membrane binding, and the contoured regions
represent the hydrophilic face that is correlated with bioactivity. It is pro-
posed that mutation of these residues reduces the propensity for self-associ-
ationand thereby indirectly leads to reducedmembranebindingandactivity.
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self-association mechanism, where the conformation of the
peptide that is capable of self-recognition is thrown into
dynamic equilibrium with other conformations. In a tetramer
dependent on multiple self-recognition interfaces any reduc-
tion in the average lifetime of each self-association face would
have a multiplicative effect on the lifetime of the entire oli-
gomer. Mutants that displayed a loss of structural rigidity as
judged by NMR (E7A and G12A) displayed a dramatic loss of
bioactivity. This is consistentwith the reduced rigidity and total
loss of activity in a series of acyclic permutants (46) and capped
acyclic permutants (47).
Analysis of the stability of two inactive mutants was under-
taken to determine if the resilience of the scaffold could be
retained while eliminating activities that would be undesirable
in pharmaceutical applications. Two mutants on loop 1 were
selected, G6A because of the presumably steric nature of its
interference with activity and E7A because of the possible
structural contribution of this residue in the wild-type peptide.
Mutant G6A was found to display similar resistance to proteo-
lytic and thermal degradation and to extremes of pH as the
wild-type peptide, consistent with a precise steric clash remov-
ing hemolytic activity in this mutant. Mutant E7A was also
found to have comparable resistance to the wild-type peptide,
indicating that the cyclic backbone and cystine knot alone are
sufficient structural features to confer extreme stability. The
resilience of both inactive mutants strengthens the potential of
the cyclotide framework for stabilization of bioactive peptide
epitopes for therapeutic applications.
Previously, it has been reported that the divalent cation
Mn2 binds to kalata B1 (41). The presence of a metal binding
sitemay be functionally significant, because it may facilitate the
interaction of kalata B1 (and other cyclotides) to membrane
surfaces, particularly anionic membrane surfaces (42). A repre-
sentative group of mutants, which were selected based on their
activity and the presence/absence of a carboxyl group, were
tested for Mn2 binding and compared with kalata B1. Kalata
B1 and the two carboxyl-containingmutants, T16A (an inactive
mutant) and T27A (an active mutant), showed very similar
responses toMn2. Significant broadening of the amide signals
from loop 1 and complete broadening of the amide signals from
loop 3 was observed, which is consistent with previous reports
and identifies themetal binding face of kalata B1 (42). At similar
concentrations of peptide andMn2, the amide signals around
the corresponding region for E7A showed significantly less
broadening, confirming that the carboxyl of Glu-7 is responsi-
ble for metal binding. This finding is consistent with the fact
that carboxyl groups have been reported to coordinate Mn2
binding in proteins (51); removal of the carboxyl in the E7A
mutant quenches the binding. Because the inactive mutant
T16A bindsMn2, it appears that metal binding may not be an
important factor for the activity of the cyclotides.
The current study has clearly shown that the cyclotide frame-
work can accommodate sequence variations and maintain a
well defined structure with the native fold. Given this conser-
vation of the overall fold in the kalata B1 mutants, it appears
likely that it is the side chains that have a greater role in main-
taining the activity of the cyclotides. Such a scenario has also
been observed for other disulfide-rich peptides such as the
-conotoxins where the native -helical fold is maintained
despite the sequence diversity throughout the family, but the
selectivity and specificity for the nicotinic acetylcholine recep-
tor varies enormously based on the side chains that are available
to interact with the receptor subunits (52, 53).
In conclusion, significant advances have been made in the
understanding of the adaptability of the cyclotide framework to
modifications. Selected mutants lacking undesirable hemolytic
activity were found to retain the characteristic stability of the
framework, verifying its suitability for pharmacological appli-
cations. The conserved hydrogen-bonding network of the loop
1 glutamate to loop 3was found to play a critical functional role,
and the activity of kalata B1 was found to depend on a surface
patch of predominantly hydrophilic residues. This information
will be valuable in future experiments aimed at exploiting the
cyclic cystine knot scaffold in drug design applications.
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Fig. S1. Attenuation by Mn2+ of intensities of selected cross-peaks (HN-Hα) in 
TOCSY spectra for various mutants and kalata B1. Relative peak intensities after the 
addition of Mn2+ are shown for kalata B1 (kB1), T27A, T16A and E7A. The sequence 
of kalata B1 is shown at the bottom of the panel with each loop labelled. The black 
arrows highlight regions that have been significantly broadened.  
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